Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Director James Edward Doyle of Exact Sciences Corp (NASDAQ:EXAS), a healthcare company with an $11.05 billion market capitalization, sold 2,000 shares of common stock on October 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro analysis, the stock is currently trading above its Fair Value.
The shares were sold at a price of $60, totaling $120,000. The timing of the sale coincides with the stock’s strong performance, having gained nearly 36% over the past six months. Following the transaction, Doyle directly owns 57,962 shares of Exact Sciences Corp. InvestingPro data reveals 8 additional key insights about EXAS’s financial health and market position.
The sale was executed under a Rule 10b5-1 trading plan established on March 9, 2025. The filing was signed on behalf of James Edward Doyle by Mark Busch, attorney-in-fact, on October 10, 2025.
In other recent news, Exact Sciences has launched Cancerguard, a new multi-cancer early detection blood test in the United States. This laboratory-developed test is priced at $689 and can detect over 50 types of cancer, including pancreatic, ovarian, and lung cancers. A new study published in the Journal of the National Cancer Institute highlights the efficiency of Cologuard Plus for colorectal cancer screening, reinforcing its role as a noninvasive option. Analysts have been adjusting their price targets for Exact Sciences, reflecting various developments. Piper Sandler raised its price target to $70, citing growth potential in the Cologuard franchise and opportunities in Cancerguard and Minimal Residual Disease testing. Benchmark also increased its target to $60, aligning with the comparable group average. Conversely, BTIG lowered its price target to $60 following Exact Sciences’ recent deal with Freenome, a move described as surprising by their analyst. These developments indicate a dynamic phase for Exact Sciences, with significant attention on its cancer detection technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.